



Biomedical Alliance in Europe

UPDATE OCTOBER 2019

Highlights:

1. ECCO Joins BioMed Alliance as a new member 1
2. Call for experts to evaluate medical devices 1
3. Support open letter to add research to title new Commissioner 1
4. Open consultation next public-private partnership for health 2
5. BioMed Alliance co-organises session translational research in Berlin 2
6. First meeting IVD Working Group takes place early November 2
7. Achievements 3
8. Upcoming 3



1. ECCO Joins BioMed Alliance as a new member



The European CanCER Organisation (ECCO) has joined the BioMed Alliance as a new member bringing our membership to a total of 32 societies. We are happy that the ECCO Board and new CEO have made the decision to participate in our growing Alliance and we are looking forward to working with them again on a number of common projects.

[ECCO](#) is a not-for-profit federation focussed on oncology that advocates for the right of all European cancer patients to high-quality treatment and care, promoting interaction between all organisations involved in cancer at European level. It is a multidisciplinary organisation that has 27 Member Societies representing over 150 000 professionals.

2. Call for experts to evaluate medical devices



The European Commission has opened a call for experts to be appointed as members of the **expert panels for medical devices**. The call is **open until 10 November 2019** for all eligible applicants with expertise related to medical devices.

By participating, experts will contribute to ensuring the safety of medical devices. They will review the clinical evidence submitted for approval of high-risk medical devices and provide advice to e.g. the European Commission, Notified Bodies and Manufacturers.

In total, around 246 experts are needed to take place in the different thematic panels. The time commitment is around 2-3 days per month (mostly remote work) and experts are remunerated. More information is available [here](#).

3. Support open letter to add research to title new Commissioner



The BioMed Alliance has joined thousands of academics, European organisations and Nobel-prize winners in signing an open letter calling on the Commission to revise the new job title of Commissioner Mariya Gabriel to include a reference to research. The Board of Directors fully supports the initiative to request changing her official title to 'Commissioner for Education, Research, Innovation and Youth' as they consider that this better reflects the broad portfolio of the Commissioner.

The BioMed Alliance believes that research is vital to European wellbeing and prosperity and that its importance should be recognised by continuing including the word research in the job title of the Commissioner. More information about this initiative is available here: <http://www.futureofresearch.eu>

In addition, we have sent a welcome letter to Commissioner Mariya Gabriel. We requested to meet her and her team soon to present the BioMed Alliance's work on boosting biomedical research and to discuss solutions on how to increase cross-fertilisation and coordination across Horizon Europe's programmes.



4. Open consultation next public-private partnership for health

Next Public Private Partnership



The public consultation for the European Partnership for Health Innovation (the successor of the Innovative Medicines Initiative or IMI) is now open for feedback. Industry organisations COCIR, EFPIA, MedTech Europe, EuropaBio and Vaccines Europe have jointly drafted a Strategic Agenda for Innovation in Healthcare which will guide the future public-private partnership.

The public consultation is open until **24 November** and results will help shape the next European Public-Private Partnership on Health Innovation. In addition, the leading organisations are organising a webinar on 4 November to provide more information and answer any questions participants may have. Once approved, the European Partnership for Health Innovation will come into effect in 2021. More information is available here: <https://www.euhealthppp.org/consultation>.

The BioMed Alliance BofD provided a first round of feedback following a joint webinar organised this summer. As a result, we will further discuss the structure and rules of engagement of the next Public-Private Partnership at a roundtable meeting with the industry on 19 November.

5. BioMed Alliance co-organises session translational research in Berlin



Join us on 7 November in Berlin to discuss the future of medicine during the Berlin Science Week. We will assist in the organisation of a session on the Value of Translational Research in Europe during the Science Match Future Medicine Conference.

The annual conference is jointly organised by the Berlin Institute of Health and Tagesspiegel and it brings together around 800 participants for discussions on new developments in medicine. This year's event focusses on translational medicine.

More information is available here: <https://bit.ly/2BeLyxn>

6. First meeting IVD Working Group takes place early November



The first meeting of the BioMed Alliance working group on In Vitro Diagnostics (IVD) is taking place on 12 November. This meeting will include experts from medical societies and experts from e.g. the European Commission and notified bodies. The meeting will focus on exchanging information on

the new Regulation for In Vitro Diagnostics (IVDR) and on exploring how medical societies can support regulators in the implementation.

The new regulation will significantly affect the evaluation and approval processes of in vitro diagnostics and medical professional input is essential for effective implementation.

The first meeting of the taskforce will focus on the requirements of the IVDR and will define the future objectives and activities of the working group. For more information, contact: Marieke.meijer@biomedeuropa.org



7. Achievements



Former BioMed Alliance Board Member *Prof. Ulrich Jäger* of the EHA has been elected as co-chair of the European Medicines Agency's Healthcare Professionals' Working Party. He will preside this group for the coming three years.

Prof. Tobias Welte, current member of the BioMed Alliance Board of Directors, has been awarded a Balzan Prize with his team. It is the second highest donated science prize (750.000 SF) and it was awarded to the German Center for Lung Research represented by Erika von Mutius (Munich), Klaus Rabe (Kiel), Werner Segger (Giessen) and Prof. Welte (Hannover) for their common merits regarding Pathophysiology of breathing.

8. Upcoming

- On 7 November, the BioMed Alliance and the Berlin Institute for Health will assist Tagesspiegel in organising a **session on translational research** during the Future Medicine conference in the Berlin Science Week. The event will include a panel discussion with key speakers exploring different aspects related to the value of translational research.
- The first meeting of the **In Vitro Diagnostics working group** will take place on 12 November in our office.
- The [European Patients Forum Congress](#) will take place from 12-14 November in Brussels. BioMed Alliance Executive Director Michel Ballieu will participate as a panellist in the session on the role of patients in professional education on 14 November.
- We will organise a **workshop on Horizon Europe** (the EUs next Research and Innovation Framework Programme) with the EAU on 19 November from 14.00-18.00 in Brussels. More information will follow, please confirm your attendance to: Marieke.meijer@biomedeuropa.org
- The BioMed Alliance **General Assembly 2019** takes place on 20 November from 10.00-16.00.
- On 31 January, we are organising a **workshop with FEAM on the future of health research in Europe** in the European Parliament.
- The 2nd **EU Health Summit** organised by the EU Health Coalition (in which the BioMed Alliance leads the research & innovation policy group), will take place on 27 and 28 April 2020 in Brussels.

